Also trades as: NAMSW (NASDAQ) · $vol 0M
NAMS NASDAQ
NewAmsterdam Pharma Company N.V.
1W: +2.8%
1M: -9.3%
3M: -33.5%
YTD: -34.1%
1Y: -21.0%
3Y: +154.9%
5Y: +135.5%
$23.20
-0.96 (-3.97%)
Weekly Expected Move ±8.4%
$19
$21
$23
$25
$27
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$769M
-11.0% ▼
5Y CAGR: +40.6%
Total Liabilities
$86M
-19.9% ▼
5Y CAGR: +47.2%
Shareholders Equity
$683M
-9.8% ▼
5Y CAGR: +39.9%
Cash & Investments
$636M
-23.7% ▼
5Y CAGR: +241.7%
Total Debt
$202K
-54.9% ▼
Net Debt
-$490M
+36.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $60M | $468M | $340M | $772M | $490M |
| Short-Term Investments | $0 | $0 | $0 | $62M | $146M |
| Cash & ST Investments | $60M | $468M | $340M | $834M | $636M |
| Net Receivables | $0 | $0 | $2M | $21M | $23M |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $5M | $2M | $0 | $0 | $1M |
| Total Current Assets | $67M | $478M | $347M | $863M | $676M |
| Property, Plant & Equip. | $216K | $154K | $101K | $673K | $568K |
| Goodwill & Intangibles | $0 | $208K | $170K | $534K | $407K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $817K | $156K | $35K | $0 | $93M |
| Total Non-Current Assets | $1M | $518K | $306K | $1M | $94M |
| Total Assets | $68M | $478M | $347M | $865M | $769M |
| — Liabilities — | |||||
| Accounts Payable | $7M | $12M | $17M | $5M | $9M |
| Short-Term Debt | $0 | $0 | $0 | $246K | $136K |
| Deferred Revenue | $0 | $0 | $9M | $6M | $4M |
| Other Current Liabilities | $0 | $18M | $16M | $91M | $73M |
| Total Current Liabilities | $11M | $36M | $50M | $107M | $86M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $66K |
| Other Non-Current Liab. | $0 | $12M | $8M | $0 | $0 |
| Total Non-Current Liabilities | $126K | $12M | $9M | $202K | $66K |
| Total Liabilities | $11M | $48M | $59M | $107M | $86M |
| — Equity — | |||||
| Common Stock | $129K | $10M | $10M | $13M | $14M |
| Retained Earnings | -$39M | -$140M | -$317M | $0 | -$762M |
| Accumulated OCI | $672K | $4M | $4M | $4M | $5M |
| Total Stockholders Equity | $57M | $430M | $288M | $758M | $683M |
| Total Liabilities & Equity | $68M | $478M | $347M | $865M | $769M |
| — Key Metrics — | |||||
| Total Debt | $187K | $126K | $60K | $448K | $202K |
| Net Debt | -$60M | -$468M | -$340M | -$771M | -$490M |
| Total Investments | $0 | $0 | $0 | $62M | $146M |